Search Results

The global genetic analysis market was evaluated at USD 10.55 billion in 2023 and is expected to attain around USD 23.60 billion by 2033

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.

Baylor Genetics today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS).

Bionano Genomics, Inc., announced that optical genome mapping was included for the first time in the American College of Medical Genetics and Genomics technical laboratory standards documentation for solid tumor analysis.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.

3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.

Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment, has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer.

Bionano Genomics, Inc., announced significant upgrades to its pipeline for analysis of optical genome mapping data in its VIA™ software for applications in constitutional genetic disease.